MBL or CLL:: Which classification best categorizes the clinical course of patients with an absolute lymphocyte count ≥ 5x109L-1 but a B-cell lymphocyte count < 5x109L-1?

被引：35

作者：

Shanafelt, Tait D. ^{[1
]}

Kay, Neil E. ^{[1
]}

Call, Tim G. ^{[1
]}

Zent, Clive S. ^{[1
]}

Jelinek, Diane F. ^{[1
]}

LaPlant, Betsy ^{[1
]}

Morice, William G. ^{[1
]}

Hanson, Curtis A. ^{[1
]}

机构：

[1] Mayo Clin, Coll Med, Rochester, MN 55905 USA

来源：

LEUKEMIA RESEARCH | 2008年 / 32卷 / 09期

关键词：

monoclonal B-cell lymphocytosis; chronic lymphocytic leukemia; diangosis; prognosis;

D O I：

10.1016/j.leukres.2007.11.030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To eliminate overlap with monoclonal B-cell lymphocytosis (MBL), some have proposed basing the diagnosis of chronic lymphocytic leukemia (CLL) on B lymphocyte count rather than absolute lymphocyte count (ALC). Such criteria should be based, in part, on patient outcomes. We evaluated the clinical implications of the proposed re-classification in 112 consecutive, newly diagnosed, Rai stage 0 patients. The new criteria would have changed the diagnosis from CLL to MBL in 47/112 (42%) patients. There was no difference in time to treatment (TTT) between those classified as MBL and CLL under the new criteria. In contrast, CD38 predicted TTT (p = 0.02) regardless of the proposed new classification. Molecular characteristics of the leukemic clone are a better predictor of progression than an arbitrary ALC or B lymphocyte count threshold. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：1458 / 1461

页数：4

共 8 条

[1] National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment [J].